Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Safety, Tolerability, Pharmacokinetics, and Quantitative EEG Study of CX-8998 in Adolescents and Adults With Idiopathic Generalized Epilepsy With Absence Seizures

NCT03406702 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.

NCT NCT03406702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03406702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Safety, Tolerability, Pharmacokinetics, and Quantitative EEG Study of CX-8998 in Adolescents and Adults With Idiopathic Generalized Epilepsy With Absence Seizures
Lead sponsor
Jazz Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
February 25, 2018
Completion date
March 29, 2019
Enrollment
7 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy